<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027295</url>
  </required_header>
  <id_info>
    <org_study_id>ACCEL-CXL-001</org_study_id>
    <nct_id>NCT05027295</nct_id>
  </id_info>
  <brief_title>Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light</brief_title>
  <official_title>A Randomized Study to Evaluate the Safety and Efficacy of Corneal Collagen Crosslinking Performed With Continuous vs Pulsed UVA Light for Reducing Corneal Curvature in Eyes With Keratoconus and Post-refractive Corneal Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornea and Laser Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea and Laser Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal collagen crosslinking has been demonstrated as an effective method of reducing&#xD;
      progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing&#xD;
      the steepness of the cornea in these pathologies.&#xD;
&#xD;
      Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of&#xD;
      the cornea, which may improve the crosslinking efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-site study to analyze the use of continuous vs pulsed UVA light&#xD;
      after removal of the epithelium for the collagen crosslinking procedure for keratoconus and&#xD;
      post-refractive corneal ectasia. In the standard crosslinking treatment, the cornea is&#xD;
      treated with a continuous UVA light treatment with a power of 3mW/cm2 for 30 minutes. CXL&#xD;
      treatment can potentially be performed in a shorter period of time by increasing the power of&#xD;
      the UVA light and decreasing the exposure time, while maintaining the same total energy&#xD;
      delivered to the cornea. This study will compare the efficacy and safety of accelerated&#xD;
      crosslinking using either a continuous or pulsed UVA treatment. One group will be randomized&#xD;
      to be treated with 12mW/cm2 of continuous UVA light treatment for 7.5 minutes and the other&#xD;
      group will be treated with 12mW/cm2 of pulsed UVA light treatment for 15 minutes.&#xD;
&#xD;
      The primary efficacy parameter that will be evaluated over time is maximum keratometry (Kmax)&#xD;
      in the randomized eyes for each treatment group. The secondary efficacy parameter is to&#xD;
      determine if the two treatment groups are equivalent in their mean Kmax change at 6 months&#xD;
      after treatment compared with baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum keratometry</measure>
    <time_frame>6 months</time_frame>
    <description>The change in maximum keratometry (Kmax) from baseline will be evaluated at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean keratometry</measure>
    <time_frame>6 months</time_frame>
    <description>Determine whether the two treatment groups are equivalent in their mean keratometry (meanK) change at 6 months post treatment compared with baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Continuous UVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of continuous UVA light for 7.5 minute exposure time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulsed UVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of pulsed UVA light for 15 minute exposure time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riboflavin ophthalmic solution</intervention_name>
    <description>Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.</description>
    <arm_group_label>Continuous UVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riboflavin ophthalmic solution</intervention_name>
    <description>Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes</description>
    <arm_group_label>Pulsed UVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older having a diagnosis of keratoconus or corneal ectasia after&#xD;
             corneal refractive surgery&#xD;
&#xD;
          -  Presence of central or inferior corneal steepening on the Pentacam map&#xD;
&#xD;
          -  Axial topography consistent with keratoconus or post-surgical corneal ectasia&#xD;
&#xD;
          -  Contact lens wearers only: removal of contact lenses for the required period of 1 week&#xD;
             prior to the screening refraction&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eyes classified as either normal, atypical normal, or keratoconus suspect on the&#xD;
             severity grading scheme&#xD;
&#xD;
          -  Corneal pachymetry measuring 300 microns or less at the thinnest point measured by&#xD;
             Pentacam in the eye(s) to be treated&#xD;
&#xD;
          -  Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of corneal disease (e.g. herpes simplex, herpes zoster keratitis,&#xD;
                  recurrent corneal erosion syndrome, corneal melt, corneal dystrophy, etc.&#xD;
&#xD;
               2. Clinically significant scarring in the CXL treatment zone&#xD;
&#xD;
          -  A history of chemical injury or delayed healing in the eye(s) to be treated&#xD;
&#xD;
          -  Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          -  A known sensitivity to study medications&#xD;
&#xD;
          -  Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment or other diagnostic tests&#xD;
&#xD;
          -  Patients with current condition that, in the investigator's opinion, would interfere&#xD;
             with or prolong epithelial healing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Hersh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cornea and Laser Eye Institute, Hersh Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BethAnn Furlong-Hibbert</last_name>
    <phone>(201) 692-9434</phone>
    <email>bfurlong-hibbert@vision-institute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Lazar</last_name>
    <phone>(201) 692-9434</phone>
    <email>slazar@vision-institute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cornea and Laser Eye Institute, Hersh Vision Group</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BethAnn Furlong-Hibbert</last_name>
      <phone>201-692-9434</phone>
      <email>bfurlong-hibbert@vision-institute.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Lazar</last_name>
      <phone>(201) 694-9434</phone>
      <email>slazar@vision-institute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven A Greenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>corneal ectasia</keyword>
  <keyword>collagen crosslinking</keyword>
  <keyword>riboflavin</keyword>
  <keyword>crosslinking</keyword>
  <keyword>corneal crosslinking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

